OBJECTIVES: While plasma biomarkers have been proposed to aid in the clinical diagnosis of Alzheimer disease (AD), few biomarkers have been validated in independent patient cohorts. Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI). METHODS: Using a targeted proteomic approach, we measured levels of 190 plasma proteins and peptides in 600 participants from 2 independent centers (University of Pennsylvania, Philadelphia; Washington University, St. Louis, MO), and identified 17 analytes associated with the diagnosis of very mild dementia/mild cognitive impairment (MCI) or AD. Four analytes (apoE, B-type natriuretic peptide, C-reactive protein, pancreatic polypeptide) were also found to be altered in clinical MCI/AD in the ADNI cohort (n = 566). Regression analysis showed CSF Aβ42 levels and t-tau/Aβ42 ratios to correlate with the number of APOE4 alleles and plasma levels of B-type natriuretic peptide and pancreatic polypeptide. CONCLUSION: Four plasma analytes were consistently associated with the diagnosis of very mild dementia/MCI/AD in 3 independent clinical cohorts. These plasma biomarkers may predict underlying AD through their association with CSF AD biomarkers, and the association between plasma and CSF amyloid biomarkers needs to be confirmed in a prospective study.
OBJECTIVES: While plasma biomarkers have been proposed to aid in the clinical diagnosis of Alzheimer disease (AD), few biomarkers have been validated in independent patient cohorts. Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI). METHODS: Using a targeted proteomic approach, we measured levels of 190 plasma proteins and peptides in 600 participants from 2 independent centers (University of Pennsylvania, Philadelphia; Washington University, St. Louis, MO), and identified 17 analytes associated with the diagnosis of very mild dementia/mild cognitive impairment (MCI) or AD. Four analytes (apoE, B-type natriuretic peptide, C-reactive protein, pancreatic polypeptide) were also found to be altered in clinical MCI/AD in the ADNI cohort (n = 566). Regression analysis showed CSF Aβ42 levels and t-tau/Aβ42 ratios to correlate with the number of APOE4 alleles and plasma levels of B-type natriuretic peptide and pancreatic polypeptide. CONCLUSION: Four plasma analytes were consistently associated with the diagnosis of very mild dementia/MCI/AD in 3 independent clinical cohorts. These plasma biomarkers may predict underlying AD through their association with CSF AD biomarkers, and the association between plasma and CSF amyloid biomarkers needs to be confirmed in a prospective study.
Authors: Alice S Chen-Plotkin; William T Hu; Andrew Siderowf; Daniel Weintraub; Rachel Goldmann Gross; Howard I Hurtig; Sharon X Xie; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Vivianna M Van Deerlin; Virginia M-Y Lee; Holly Soares; John Q Trojanowski Journal: Ann Neurol Date: 2010-11-29 Impact factor: 10.422
Authors: Christopher M Clark; Sharon Xie; Jesse Chittams; Douglas Ewbank; Elaine Peskind; Douglas Galasko; John C Morris; Daniel W McKeel; Martin Farlow; Sharon L Weitlauf; Joseph Quinn; Jeffrey Kaye; David Knopman; Hiroyuki Arai; Rachelle S Doody; Charles DeCarli; Susan Leight; Virginia M-Y Lee; John Q Trojanowski Journal: Arch Neurol Date: 2003-12
Authors: Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski Journal: Acta Neuropathol Date: 2014-01-03 Impact factor: 17.088
Authors: William T Hu; Kelly Watts; Murray Grossman; Jonathan Glass; James J Lah; Chadwick Hales; Matthew Shelnutt; Vivianna Van Deerlin; John Q Trojanowski; Allan I Levey Journal: Neurology Date: 2013-10-30 Impact factor: 9.910
Authors: Sid E O'Bryant; Leigh Johnson; Melissa Edwards; Holly Soares; Michael D Devous; Sarah Ross; Geoffrey Rohlfing; James Hall Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472